WCN26-1959 ASSOCIATION OF TIRZEPATIDE WITH KIDNEY PARAMETERS IN PEOPLE WITH OBESITY AND PREDIABETES FROM SURMOUNT-1 OVER 176 WEEKS

Read full text Summarise with VIRAT
Authors: Hiddo J.L. Heerspink, Daniël H. van Raalte, Katherine Tuttle, David Z.I. Cherney, Petter Bjornstad, Carolina Piras de Oliveira, Georgios K. Dimitriadis, Dachuang Cao, Bruno Linetzky, Irina Jouravskaya, Ryan M. Griffin, Yusuke Takahashi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Obesity and type 2 diabetes (T2D) lead to kidney damage and decline in function over time. Tirzepatide (TZP) has been associated with kidney protective effects in people with T2D and with improvements in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) in people with obesity or overweight after 72 weeks of treatment. The current analysis aimed to determine if improvements in kidney parameters persist over 176 weeks of TZP treatment in people with obesity and prediabetes.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Diabetes Management and Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104589–104589
Publication date
25 March 2026
Language
EN